BDR Pharmaceutical launches generic drug for treating prostate cancer

The drug has been launched under the brand APATIDE in India to treat both metastatic castration sensitive as well as non-metastatic castration resistant prostate cancer

FPJ Web DeskUpdated: Tuesday, January 03, 2023, 03:58 PM IST
article-image
BDR Pharmaceutical launches generic drug for treating prostate cancer | Image credit: BDR (Representative)

BDR Pharmaceutical on Tuesday said it has launched its generic version of Apalutamide, used in the treatment of prostate cancer, in India.

According to a statement from the firm, the medication is now available in India under the brand name APATIDE to treat both metastatic castration sensitive prostate cancer and non-metastatic castration resistant prostate cancer.

The product will be available at 60 mg strength in two packs of 60 tablets and 120 tablets.

BDR Group Director Business Development, Raheel Shah said that the launch of APATIDE is "testimony towards our commitment in providing access to affordable medicines without compromising patients' safety as well as qualitative standards".

The company produces cancer medications in India and specialises in the production of pharmaceutical active components and cutting-edge formulations.

(If you have a story in and around Mumbai, you have our ears, be a citizen journalist and send us your story here. )

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Here's why stamp duty is payable on the exchange of flats

Here's why stamp duty is payable on the exchange of flats

6 smart ways to manage gap funding

6 smart ways to manage gap funding

The evolution in residential projects is evident in central suburban areas like Sion-Chunabhatti and...

The evolution in residential projects is evident in central suburban areas like Sion-Chunabhatti and...

Before Ashneer Grover's exit, BharatPe lost Rs 5,610.7 cr in FY22

Before Ashneer Grover's exit, BharatPe lost Rs 5,610.7 cr in FY22

Powergrid's pre-qualification norms for drone project seen as restrictive

Powergrid's pre-qualification norms for drone project seen as restrictive